ArticleThe Canadian journal of hospital pharmacy2025
Canadian Monitoring Program for Surface Contamination with 11 Antineoplastic Drugs in 126 Centres: Results for 2023.
Article in The Canadian journal of hospital pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Jack (and Jill) of All Trades.The Canadian journal of hospital pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Occupational exposure to antineoplastic drugs can lead to long-term adverse effects on workers' health. Objective: To describe contamination with 11 antineoplastic drugs measured on surfaces within health care centres. Methods: Centres sampled 12 standardized sites: 6 in oncology pharmacies and 6 in outpatient clinics. Samples were analyzed by ultra-performance liquid chromatography-tandem mass spectrometry. Results: A total of 126 Canadian centres participated over the period January to April 2023. Cyclophosphamide (411/1476, 28%) and gemcitabine (352/1476, 24%) were frequently found on surfaces; less than 10% of samples were contaminated with the other 9 drugs. The 90th percentile of concentration was 0.0095 ng/cm Conclusions: This monitoring program allowed centres to benchmark their contamination and helped increased awareness. Frequent decontamination, safe handling practices, and the use of personal protective equipment are mandatory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.